Clinical trial
Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV…
NCT00425737 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00425737 |
|---|---|
| Title | Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants |
| Official title | A Study to Assess the Efficacy, Immunogenicity and Safety of Two Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix) in Healthy Infants. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Infections, Rotavirus |
| Intervention type | Biological |
| Interventions | Rotarix |
| Enrollment | 405 |
| Start date | Aug 1, 2000 |
| Primary completion | Jul 1, 2001 |
| Completion | Jul 1, 2001 |
| First posted | Jan 23, 2007 |
| Last update posted | Sep 16, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: